

JUL 01 2004

**KILPATRICK
STOCKTON LLP**

Attorneys at Law

OFFICIAL

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
t 404 815 6500 f 404 815 6555
www.KilpatrickStockton.comdirect dial 404 815 6102
direct fax 404 541 3454
EPolovnikova@KilpatrickStockton.com

July 1, 2004

FAX

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Examiner N. Alonzo Art Unit 1632 571-272-2910	703-872-9306	Commissioner for Patents Alexandria, Virginia

John K. McDonald, Ph.D.

FROM

7

PAGES (WITH COVER)

7770

REFERENCE NO

43150-286808

CLIENT/MATTER NO.

PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

CONFIDENTIALITY NOTE:

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

The facsimile confirmation of the Patent Office imprinted hereon will acknowledge receipt of:

Serial No: 10/618,839

Filing Date: July 14, 2003

Inventor: J. David LAMBETH et al.

For: Methods and Transgenic Mouse Model for Identifying and Modulating Factors Involved
in the Production of Reactive Oxygen Intermediates

Papers Submitted: Transmittal; Response to Restriction Requirement

Docket No.: 43150/286808 (05501-0211)

Date Mailed July 1, 2004

Atty/Sec: JKM:SCM:ckf

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME: _____

COMPLETED BY: _____

JOB CODE

02462

ATLANTA AUGUSTA CHARLOTTE LONDON MIAMI RALEIGH RESTON STOCKHOLM WASHINGTON WINSTON-SALEM

JUL 01 2004

PATENTS

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of: **J. David Lambeth, et al.**

Docket No. 05501-0211 (43150-286808)

Serial No. 10/618,839

Filed: **July 14, 2003**For: **METHODS AND TRANSGENIC MOUSE MODEL FOR IDENTIFYING AND
MODULATING FACOTRS INVOLVED IN THE PRODUCTION OF REACTIVE
OXYGEN INTERMEDIATES**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

Sir:

Transmitted herewith is a paper in the above-identified application.

- ☒ Response to Restriction Requirement.
☒ Applicant claims small entity status.
☒ No additional fee is required.

					SMALL ENTITY		OTHER THAN SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	16	MINUS	26=	0	x9	\$	x18	\$
INDEP.	1	MINUS	3=	0	x43	\$	x86	\$
FIRST PRESENTATION OF								
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+145	\$	+290	\$
TOTAL						\$0	\$	
ADDITIONAL FEE						\$0	\$	

- ☐ A check in the amount of \$ is attached.
☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being sent by
 facsimile transmission to the Commissioner for Patents
 to 703-872-9306 attention Examiner Norma C. Alonzo
 on July 1, 2004.


 John K. McDonald, Ph.D.

KILPATRICK STOCKTON LLP
 1100 Peachtree Street
 Suite 2800
 Atlanta, Georgia 30309-4530
 Telephone: 404/815-6500

By: 

John K. McDonald, Ph.D.
 Attorney for Applicant
 Reg. No. 42,860

JUL 01 2004

OFFICIAL

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

J. DAVID LAMBETH

Serial No. 10/618,839

Filed: July 14, 2003

For: **METHODS AND TRANSGENIC MOUSE
MODEL FOR IDENTIFYING AND
MODULATING FACTORS INVOLVED
IN THE PRODUCTION OF REACTIVE
OXYGEN INTERMEDIATES**)
)
)
)
) Art Unit: 1632
)
)
) Examiner: N. Alonzo
)
)
)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Dear Sir :

Responsive to the Office Action mailed on June 1, 2004, please consider the following remarks.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 11-0855.

Remarks begin on Page 2 of this paper.

I hereby certify that this correspondence is being sent by facsimile transmission to the Commissioner for Patents to 703-872-9306 attention Examiner Norma C. Alonzo on July 1, 2004.


John K. McDonald, Ph.D. - Reg. 42,860

Response to Restriction Requirement
Serial No. 10/618,839
Page 2 of 5

Remarks

In the Restriction Requirement mailed June 1, 2004, the Examiner divided the claims into 15 groups:

Group I: Claims 1-6, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:1, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group II: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:3, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group III: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:5, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group IV: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:7, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group V: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:9, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group VI: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:11, a cell or cell line derived from said

Response to Restriction Requirement
Serial No. 10/618,839
Page 3 of 5

transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group VII: Claims 1-5, 9-17 and 26 drawn to a transgenic non-human animal comprising the sequence of SEQ ID NO:13, a cell or cell line derived from said transgenic non-human animal and a method of using said transgenic non-human animal. (Class 800, subclass 8)

Group VIII: Claims 7-8 and 19-20 drawn to a transgenic non-human animal comprising a transgene encoding a NADPH oxidase enzyme or dual oxidase enzyme and further comprising a nonsense mutation in a murine adenomatous polyposis coli gene, and a method for using said transgenic non-human animal. (Class 800, subclass 8)

Group IX: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:1, a cell containing the said vector. (Class 435, subclass 325)

Group X: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:3, a cell containing the said vector. (Class 435, subclass 325)

Group XI: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:5, a cell containing the said vector. (Class 435, subclass 325)

Group XII: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:7, a cell containing the said vector. (Class 435, subclass 325)

Group XIII: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:9, a cell containing the said vector. (Class 435, subclass 325)

Response to Restriction Requirement
Serial No. 10/618,839
Page 4 of 5

Group XIV: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:11, a cell containing the said vector. (Class 435, subclass 325)

Group XV: Claims 21-25 drawn to a vector comprising a transgene wherein the transgene is SEQ ID NO:13, a cell containing the said vector. (Class 435, subclass 325)

In response, Applicants elect Group I directed to a transgenic non-human animal comprising the sequence of SEQ ID NO:1, a cell or cell line derived from said transgenic non-human animal, and a method of using said transgenic non-human animal. This election is made with traverse.

The Current Restriction Requirement is Improper

The current restriction requirement divides a transgenic animal and a vector into fifteen inventions. Claims 1-5, 7-20, 21-25 and 26 are all generic and do not specify a transgene. The current restriction attempts to impose limitations on the claims through the vehicle of restriction requirement.

At the very most, the claims should be restricted to two groups of claims for prosecution, (claims 1- 20 and 26 are directed to a transgenic animal and claims 21-25 are directed to a vector comprising a transgene) with an election of species for the transgene. The Manual of Patent Examining Procedure states "[i]f the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions." (MPEP 803)

Rejoinder of the claims would not present an undue burden for the Examiner to search because groups I-VIII are all in the same class/subclass (Class 800, subclass 8). Similarly, groups IX-XV are also in the same class/subclass (Class 435, subclass 325).


Response to Restriction Requirement
Serial No. 10/618,839
Page 5 of 5

Applicants note that claim 18 was not included in any of the fifteen groups of claims cited by the Examiner.

Applicants were also required to elect one species of promoter for search purposes on the understanding that upon allowance of a generic claim, claims to the additional species will be considered if they are written in dependent form or otherwise include all the limitations of the allowed generic claim. In response, Applicants elect the CX1 promoter.

Rejoinder and examination of the claims is respectfully solicited.

Respectfully submitted,


John K. McDonald, Ph.D.
Reg. No. 42,860

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
Tel. (404) 745-2470
Attorney Docket No. 05501-0211 (43150-286808)